Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910